![Roche - APHINITY study shows Roche's Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Roche - APHINITY study shows Roche's Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer](https://www.roche.com/dam/jcr:f64cd884-b5fb-4bc5-8696-9e1b20568add/de/med-cor-2017-06-05-table-1.2017-06-02-17-59-48.jpg)
Roche - APHINITY study shows Roche's Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
![Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579 Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579](https://thumbs.worthpoint.com/zoom/images2/164/0317/02/amber-inclusions-hymenaea-protera_164_66aa511bc736d03eff99fe80b53e13be.jpg)
Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579
![Roche - APHINITY six-year results strengthen evidence of clinical benefit with Roche's Perjeta-based regimen Roche - APHINITY six-year results strengthen evidence of clinical benefit with Roche's Perjeta-based regimen](https://www.roche.com/dam/jcr:9c2e4291-b9e9-428d-b7fc-b6641f6afe89/en/med-cor-11-12-2019-table.2019-12-10-17-17-08.jpg)
Roche - APHINITY six-year results strengthen evidence of clinical benefit with Roche's Perjeta-based regimen
![Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579 Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579](https://thumbs.worthpoint.com/zoom/images3/164/0317/02/amber-inclusions-hymenaea-protera_164_66aa511bc736d03eff99fe80b53e13be.jpg)
Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579
![Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579 Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579](https://thumbs.worthpoint.com/zoom/images1/164/0317/02/amber-inclusions-hymenaea-protera_164_66aa511bc736d03eff99fe80b53e13be.jpg)
Amber with Inclusions -- Hymenaea protera Miocene Dominican Republic 1.02 x 0.73 x 0.46 inches (2.60 x 1.85 x 1.17 cm) | #1891288579
![Roche - APHINITY study shows Roche's Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Roche - APHINITY study shows Roche's Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer](https://www.roche.com/dam/jcr:bc376745-18ef-4ef0-b97b-12e4025974d8/de/Understanding-her2-positive-breast-cancer-teaser.jpg)